- Home
- EXPE vs RPRX Comparison
EXPE vs RPRX Comparison
Compare EXPE & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXPE | RPRX |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1B | 22.0B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EXPE | RPRX |
|---|---|---|
| Price | $267.77 | $57.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 5 |
| Target Price | ★ $275.89 | $51.40 |
| AVG Volume (30 Days) | 1.5M | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | 0.77% | ★ 1.90% |
| EPS Growth | ★ 9.61 | N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | ★ $14,733,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $10.35 | $38.63 |
| Revenue Next Year | $6.93 | $4.73 |
| P/E Ratio | ★ N/A | $86.22 |
| Revenue Growth | ★ 7.61 | 5.06 |
| 52 Week Low | $174.10 | $34.63 |
| 52 Week High | $303.80 | $57.79 |
Technical Indicators
Market Signals| Indicator | EXPE | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 63.95 |
| Support Level | $265.01 | $38.07 |
| Resistance Level | $279.96 | N/A |
| Average True Range (ATR) | 10.25 | 1.50 |
| MACD | 3.02 | 0.16 |
| Stochastic Oscillator | 94.32 | 99.55 |
Price Performance
Historical ComparisonAbout EXPE Expedia Group Inc.
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2024 sales), air tickets (3%), rental cars, cruises, in-destination, and other (10%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and alternative accommodations brand Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.